ArticleInternational journal of clinical and experimental pathology2017
MiR-124 inhibits cell proliferation, invasion, and migration in glioma by targeting Smad2.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- The significance of miR-124 in the diagnosis and prognosis of glioma: A systematic review.PloS one · 2024Pooled it
- mRNA-based MRI contrast agent for precise diagnosis of glioma and pseudoprogression.Cell biomaterials · 2026Article
- Article
- FXR1 promotes glioma progression by downregulating microRNA-124-3p through long noncoding RNA FGD5-AS1 upregulation.Acta neurologica Belgica · 2023Article
- Altered Expression of miR-575 in Glioma is Related to Tumor Cell Proliferation, Migration, and Invasion.Neuromolecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumorigenesis research has focused on the roles of deregulated microRNAs for many years. The aberrant expression of miR-124 in many tumors has been widely reported, yet its role in glioma formation still needs further research. In this study, the expression and mechanisms of miR-124 in glioma development were explored. We found that glioma cell lines and tumor tissues demonstrated downregulated miR-124 expression, and that cell proliferation, migration, and invasion were reduced when miR-124 was restored. Furthermore, a bioinformatic analysis indicated that Smad2 was a putative target of miR-124, and we confirmed that miR-124 directly targets Smad2 in a luciferase reporter assay system. These results indicate that glioma cell growth is suppressed by miR-124 through its negative regulation of Smad2 expression. Our findings disclose a critical role of miR-124 in glioma pathogenesis, and suggest its potential application for glioma therapy.
Indexed as
Identifiers
31966492PMC6965836W3026476998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.